MaaT Pharma: share price rises on positive clinical trial

(CercleFinance.com) - MaaT Pharma posted one of the biggest gains on the Paris Bourse on Thursday, following the announcement of the success of its Phase 3 clinical trial in acute graft-versus-host disease (aGvH).


At 11:45 a.m., the share price had climbed by over 19%, taking it back to its highest level since May 2024. With this increase, MaaT has raised its market capitalization to over 134 million euros.

The MaaT013 microbiotherapy study met its primary endpoint, showing a significant overall gastrointestinal response rate of 62% at day 28, an 'unprecedented' level of efficacy.

This response rate is well above the expected response rate of 38%.

"Are we surprised by the positive results of the study?" ask analysts at Stifel, who are Buy on the stock.

"No, because there was sufficient evidence to support the efficacy of MaaT013", says the research firm.

"Are we surprised by the magnitude of its effects?", it adds. "To tell the truth, a little bit", admits Stifel.

The analyst consequently raises the product's probability of success in this indication from 80% to 95%, which leads him to raise his price target from 21 to 22 euros.

According to MaaT Pharma, the probability of survival at one year - which reaches 54% - underlines MaaT013's potential to improve long-term survival in 3rd-line GI-aGvH.

The biotech company expects to file a marketing authorization application (MAA) in Europe in mid-2025, ahead of schedule.

MaaT013 aims to restore the symbiotic relationship between the patient's gut microbiota and immune system, in order to correct reactivity and restore tolerance of immune functions, and thus reduce steroid-resistant gastrointestinal aGvH.

Copyright (c) 2025 CercleFinance.com. All rights reserved.